You are here

Article Text

Article menu
Download PDFPDF
ABN Abstracts 2022
Poster presentations
052 SKYLINE study design efficacy and safety of gantenerumab in participants at-risk for Alzheimer’s disease
  1. Szofia Bullain1,
  2. Paul Delmar1,
  3. Reisa Sperling2,3,
  4. Eric M Reiman4,
  5. Paul Aisen5,
  6. Jakub Wojtowicz6,
  7. Tobias Bittner7,
  8. Elizabeth Ashford8,
  9. Rachelle S Doody1,9,
  10. Susanne Ostrowitzki1
  1. 1F. Hoffmann-La Roche Ltd, Basel, Switzerland
  2. 2Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
  3. 3Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
  4. 4Banner Alzheimer’s Institute, Phoenix, AZ, USA
  5. 5Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA, USA
  6. 6Clinical Safety, Roche Pharma Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland
  7. 7OMNI Biomarker Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland
  8. 8Pharma Development Clinical Operations, Roche Products Ltd, Welwyn Garden City, UK
  9. 9Genentech, Inc., South San Francisco, CA, USA

Abstract

The anti-amyloid beta (Aβ) monoclonal antibody gantenerumab is in late-phase clinical development for early (prodromal-to-mild) Alzheimer’s disease (AD). SKYLINE is an upcoming Phase III multicentre, ran- domised, parallel-group, double-blind, placebo-controlled secondary prevention study, evaluating the efficacy and safety of subcutaneous gantenerumab in participants at risk for, or in the earliest stages of, AD.

SKYLINE will enrol ~1,200 cognitively unimpaired participants, aged 60–80, with confirmed Aβ pathology (cerebrospinal fluid or positron emission tomography).

Participants will be randomised 1:1 to 211 weeks’ subcutaneous gantenerumab (titrated to 1,020 mg monthly dosage) or placebo treatment administered weekly or every other week. Any participant confirmed as progressing to mild cognitive impairment or AD dementia during the study will undergo a blinded post-progression dose escalation, during which participants on placebo switch to gantenerumab. All parties will remain blinded to the assigned treatment at randomisation.

The primary endpoint is change from baseline to Year 4 in the Preclinical Alzheimer’s Cognitive Composite-5 score. Secondary and exploratory objectives include further efficacy assessments (e.g. clinical progression); safety; pharmacodynamic biomarkers; pharmacokinetics; and identification of additional biomarkers.

SKYLINE will be the first secondary prevention study of subcutaneous gantenerumab in cognitively unim- paired participants at risk for, or in the earliest stages of, AD.

https://doi.org/10.1136/jnnp-2022-abn2.96

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.